Contrary to current thinking, the group of serotypes of Streptococcus pneumoniae responsible for most invasive pneumococcal disease worldwide is conserved across regions. Streptococcus pneumoniae is the leading bacterial cause of pneumonia, sepsis, and meningitis in children, which together comprise more than 25% of the 10 million deaths estimated to have occurred in 2000 in children under 5 years of age, and preventable by access to appropriate vaccines. The serotypes currently included in existing pneumococcal conjugate vaccine formulations account for 49-88% of deaths in children under 5 in Africa and Asia, where the morbidity and mortality of pneumococcal disease are the highest, and where until recently, most children do not have access to current pneumococcal conjugate vaccines. These are the key findings of a research study in this week's PLoS Medicine by Hope Johnson from the International Vaccine Access Center, Johns Hopkins University Bloomberg School of Public Health, Baltimore, USA, and colleagues.

After an extensive literature review, which included information on 60,090 isolates of Streptococcus pneumoniae from 70 countries, the authors estimated which serotypes caused invasive pneumococcal disease among children under five in different regions of the world. They found that found seven serotypes (1, 5, 6A, 6B, 14, 19F, and 23F) were the most common globally and that these seven serotypes accounted for the majority of invasive pneumococcal disease in every region.

These important findings mean that health policy makers can assess the potential impact of serotypes included in different conjugate vaccines and vaccine manufacturers can now work from a consensus set of serotype coverage estimates to plan and design future serotype-based vaccine formulations to target local pneumococcal disease burden more accurately.

The authors say: "Our findings contradict the conventional supposition that the most common serotypes causing [invasive pneumococcal disease] vary greatly across geographic regions."

They add: "Recent progress towards increasing access to pneumococcal conjugate vaccines in high-burden countries will contribute to achieving the year 2015 Millennium Development Goal 4 target to reduce child mortality by two-thirds."

###

Funding: This work was funded by the GAVI Alliance. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Hope Johnson
Johns Hopkins University Bloomberg School of Public Health
International Health
615 N. Wolfe St
Baltimore, MD 21205
United States of America
410-502-9316
hjohnson@jhsph.edu

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.